Compare DCO & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCO | AGIO |
|---|---|---|
| Founded | 1849 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 1995 | 2013 |
| Metric | DCO | AGIO |
|---|---|---|
| Price | $149.50 | $28.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $153.60 | $38.88 |
| AVG Volume (30 Days) | 199.7K | ★ 741.6K |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $824,730,000.00 | $43,011,000.00 |
| Revenue This Year | $7.40 | $76.75 |
| Revenue Next Year | $8.59 | $170.73 |
| P/E Ratio | $232.22 | ★ N/A |
| Revenue Growth | ★ 4.85 | N/A |
| 52 Week Low | $71.40 | $22.24 |
| 52 Week High | $156.32 | $46.00 |
| Indicator | DCO | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 56.87 | 47.49 |
| Support Level | $135.11 | $26.75 |
| Resistance Level | $156.32 | $29.37 |
| Average True Range (ATR) | 5.97 | 1.13 |
| MACD | 0.24 | 0.18 |
| Stochastic Oscillator | 65.61 | 23.05 |
Ducommun Inc provides engineering & manufacturing services for high-performance products & high-cost-of failure applications used in the aerospace and defense, industrial, medical & other industries. The company's reportable segments are Structural Systems & Electronic Systems. Structural Systems designs, engineers and manufactures various sizes of complex contoured aerostructure components and assemblies and supplies composite and metal bonded structures and assemblies. Electronic Systems designs, engineers and manufactures high-reliability electronic and electromechanical products used in technology-driven markets including A&D and Industrial end-use markets. It generates maximum of its revenue from the Electronic Systems.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.